Omada Health, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
3. Fair Value Measurements
- Fair Value Measurements
The following table presents information about the Company’s financial assets measured at fair value on a recurring basis based on the fair value hierarchy as follows (in thousands):
| As of September 30, 2026 | ||||||
|---|---|---|---|---|---|---|
| Level 1 · Level 2 · Level 3 · Total | ||||||
| Assets | ||||||
| Cash and cash equivalents: | ||||||
| Money market funds | $226,982 | $ | - | $ | - | $226,982 |
| Total | $226,982 | $ | - | $ | - | $226,982 |
| As of December 31, 2025 | ||||||
|---|---|---|---|---|---|---|
| Level 1 · Level 2 · Level 3 · Total | ||||||
| Assets | ||||||
| Cash and cash equivalents: | ||||||
| Money market funds | $206,018 | $ | - | $ | - | $206,018 |
| Total | $206,018 | $ | - | $ | - | $206,018 |
Level 3 liabilities that were measured at fair value on a recurring basis consisted of Series B and D redeemable convertible preferred stock warrant liabilities and common stock warrant liabilities associated with warrants issued in connection with the Company’s financing arrangements that were cashless exercised and converted to the Company’s common stock during the year ended December 31, 2025. The Company recognized losses on the changes in the fair value of convertible preferred stock warrants and common stock warrants of $0.2 million and $1.5 million during the three and nine months ended September 30, 2025, respectively. No preferred stock warrant liabilities and common stock warrant liabilities remained outstanding as of September 30, 2026.
The Company recognizes transfers among Level 1, Level 2, and Level 3 classifications as of the actual date of the events or change in circumstances that caused the transfers. There were no transfers between fair value measurement levels during the periods presented.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.